On Jun. 10, 2020, OraSure Technologies announced it had been awarded a $629,217 contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop an Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of human anti-SARS-CoV-2 antibodies in oral fluid specimens. Currently, there are no oral fluid-based COVID antibody tests available with automated assays.